RxDoctor Payments Data

Cynthia Williams

Psychiatric/Mental Health · Frankfort, KYNPI 1396103404

Payments from drug & device makers

$3,368in general payments, 2019–2025

Across 47 payments — averaging $71.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$634
  • AbbVie$632
  • Axsome Therapeutics, Inc.$539
  • Tris Pharma Inc$242
  • Bayer$232
  • Abiomed$143
  • plus $947 from 10 others

What the payments were for

  • Food & beverage$3,368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,368 in reported general payments places this provider in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,520
Medicare patients
17
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl30$42,777
RexultiBrexpiprazole13$19,196
Lurasidone Hcl11$1,498
Buspirone Hcl43$1,290
Amitriptyline Hcl16$557
Quetiapine Fumarate30$475
Bupropion XlBupropion Hcl29$461
Hydroxyzine Hcl36$393
Duloxetine Hcl18$274
Venlafaxine Hcl ErVenlafaxine Hcl25$257
Sertraline Hcl26$234
Lorazepam32$168
Alprazolam32$156
Escitalopram Oxalate35$141
Clonazepam38$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$632$42,77730 claims
Otsuka America Pharmaceutical, Inc.Rexulti$109$19,19613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Frankfort

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →